Wednesday 19 March 2025
The way prescription drug companies negotiate prices with pharmacy benefit managers (PBMs) has long been shrouded in mystery, with some critics accusing PBMs of using their market power to stifle competition and inflate costs. A new study sheds light on this complex process, revealing that PBMs are using a combination of tactics to maximize profits while limiting the impact of new competitors.
At the heart of the issue is the way PBMs assign positions on formularies, which dictate which drugs will be covered by insurance plans. This process involves complex negotiations between the PBM and drug companies, with prices and rebates playing a crucial role. The study found that PBMs are using their market power to extract higher rebates from new entrants into the market, while also limiting the number of positions available on formularies.
The researchers used a novel approach to model this process, drawing on data from the pharmaceutical industry and insurance companies. They created a virtual PBM and simulated the negotiations between the PBM and two drug companies: an incumbent with a long history of dominance in the market, and a new entrant seeking to break into the market.
The study found that the incumbent has significant bargaining power, allowing it to extract higher rebates from the PBM while also limiting the number of positions available on formularies. This makes it difficult for new competitors to gain traction in the market, even if they offer lower prices or better quality drugs.
But there’s a twist: the study also found that the PBM’s use of lump sum rebates can actually increase the cost of prescription drugs for consumers. These rebates are paid by drug companies to secure a position on the formulary, and they can be used to offset the higher costs associated with marketing and sales.
The researchers argue that these rebates are not necessarily a bad thing, as they can help to reduce the overall cost of prescription drugs by incentivizing competition among drug companies. However, the study’s findings suggest that PBMs may be using lump sum rebates in a way that is more beneficial to themselves than to consumers.
The implications of this study are significant, particularly for patients and healthcare providers who are struggling with rising costs and limited access to new treatments. By shedding light on the complex dynamics between PBMs and drug companies, the researchers hope to inform policy makers and regulators as they work to reform the pharmaceutical industry.
Cite this article: “PBMs Negotiation Tactics: A Study Reveals the Complex Dynamics Behind Prescription Drug Prices”, The Science Archive, 2025.
Pharmacy Benefit Managers, Prescription Drug Companies, Formularies, Rebates, Market Power, Competition, Pharmaceutical Industry, Insurance Companies, Healthcare Costs, Policy Makers.
Reference: Lawrence W. Abrams, “The Market Design for Formulary Positions” (2025).
